StockNews.com Initiates Coverage on Aethlon Medical (NASDAQ:AEMD)

StockNews.com assumed coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a report published on Monday. The firm issued a sell rating on the medical equipment provider’s stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Aethlon Medical in a research report on Monday, March 10th.

Aethlon Medical Trading Down 8.4 %

Aethlon Medical stock opened at $0.33 on Monday. Aethlon Medical has a 12 month low of $0.24 and a 12 month high of $1.79. The business’s fifty day simple moving average is $0.44 and its two-hundred day simple moving average is $0.49. The company has a market capitalization of $5.28 million, a price-to-earnings ratio of -0.21 and a beta of 1.71.

Aethlon Medical (NASDAQ:AEMD) last announced its quarterly earnings data on Wednesday, February 12th. The medical equipment provider reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.09. On average, equities research analysts predict that Aethlon Medical will post -0.73 EPS for the current year.

Institutional Trading of Aethlon Medical

A number of large investors have recently made changes to their positions in the stock. Renaissance Technologies LLC bought a new position in Aethlon Medical during the fourth quarter valued at approximately $25,000. Allegiance Financial Group Advisory Services LLC purchased a new stake in Aethlon Medical during the 4th quarter valued at $26,000. Sassicaia Capital Advisers LLC purchased a new stake in Aethlon Medical during the 4th quarter valued at $31,000. Virtu Financial LLC bought a new position in shares of Aethlon Medical during the 4th quarter valued at $81,000. Finally, Boothbay Fund Management LLC purchased a new position in shares of Aethlon Medical in the 4th quarter worth $186,000. 1.99% of the stock is currently owned by institutional investors.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.